Table 4. Histoclinical features of the validation set (n=366).
| Age (years) a | |
| Median | 60 |
| Range | 33–84 |
| Histological subtype | |
| Serous | 351 (96%) |
| Endometrioid | 11 (3%) |
| Others | 4 (1%) |
| FIGO stage | |
| III | 337 (92%) |
| IV | 29 (8%) |
| Histological grade | |
| 1 | 16 (4%) |
| 2 | 132 (36%) |
| 3 | 215 (59%) |
| NI | 3 (1%) |
| Residual disease after surgery | |
| Yes | 187 (51%) |
| No | 153 (42%) |
| NI | 26 (7%) |
| Median follow-up (months)b | 32 |
| Number of deaths | 172 (112 with time of death available) |
| Five-year OS (95% CI)b | 39% (31–49) |
Abbreviations: CI=confidence interval; FIGO=Fédération Internationale de Gynécologie et Obstétrique; NI=not indicated; OS=overall survival.
a
295 samples with data available.
b
For the 262 cases with follow-up time available.